KOE:950220

NeoImmuneTech, Inc. · KOE · Healthcare · KRW · FY for 2025

Figures on this page computed 2026-11-08 13:08 UTC

Last close

n/aKRW

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed
- Computed from the filing for 2025
-81.7%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-33531.4%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
-34003.6%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.18Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed

Returns on capital is the furthest below its sector's middle: 0.13 against 0.25 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.72x

0.88x

1.01x

1.77x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales0.72x
Its own average over 2 years, 132.6M.
Profit0.88x
Its own average over 8 years, -36.34B.
Free cash flow1.01x
Its own average over 8 years, -31.81B.
Debt1.77x
Its own average over 7 years, 5.94B.
Pricen/a
Its own average over 0 years. Market data

Debt is furthest from its own average, at 1.77 times.

Sales is 0.72 times its own 2-year average; Profit is 0.88 times its own 8-year average; Free cash flow is 1.01 times its own 8-year average; Debt is 1.77 times its own 7-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 2-year average0.72
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Profit against its own 8-year average0.87
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Free cash flow against its own 8-year average1.01
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Debt against its own 7-year average1.77
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
KRW